View Older Stories

May 27, 2026 08:30AM Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

May 7, 2026 11:00AM Aspire Biopharma to implement 1-for-30 reverse stock split May 11

May 7, 2026 11:00AM Aspire Biopharma to implement 1-for-30 reverse stock split

May 7, 2026 11:00AM Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Apr 27, 2026 08:37AM Aspire Biopharma authorizes $5 million share repurchase program

Apr 27, 2026 08:30AM Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Apr 20, 2026 08:33AM Aspire Biopharma closes $21 million funding, secures $22.5 million credit line

Apr 20, 2026 08:30AM Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Apr 17, 2026 08:00AM Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Apr 16, 2026 08:31AM Aspire Biopharma signs letter of intent to acquire automotive supplier

Apr 16, 2026 08:30AM Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Apr 15, 2026 08:00AM Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Apr 15, 2026 06:32AM Aspire Biopharma signs letter of intent to acquire Driver Controls Systems

Mar 19, 2026 08:00AM Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 17, 2026 08:31AM Aspire Biopharma unit hires John Choe as western sales director

Mar 17, 2026 08:30AM Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 12, 2026 08:00AM Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 10, 2026 08:30AM Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 3, 2026 08:00AM Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Feb 25, 2026 08:30AM Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 20, 2026 08:02AM Aspire Biopharma regains full compliance with NASDAQ listing rules

Feb 20, 2026 08:00AM Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 19, 2026 08:00AM Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 17, 2026 08:38AM Aspire Biopharma files patent for sublingual meclizine powder

Feb 17, 2026 08:30AM Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 13, 2026 08:00AM Aspire Biopharma appoints Phillip Balatsos to board of directors

Feb 13, 2026 08:00AM Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 12, 2026 08:03AM Aspire Biopharma files patent for sublingual ondansetron powder

Feb 12, 2026 08:00AM Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 11, 2026 07:45AM Aspire Biopharma raises $21 million in private placement

Feb 11, 2026 07:45AM Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 10, 2026 08:01AM Aspire Biopharma regains Nasdaq minimum bid price compliance

Feb 10, 2026 08:00AM Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 5, 2026 08:00AM Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 3, 2026 08:00AM Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Jan 29, 2026 08:04AM Aspire Biopharma partners with Microsize for sublingual aspirin development

Jan 29, 2026 08:00AM Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 27, 2026 08:04AM Aspire Biopharma files patent for sublingual clopidogrel formulation

Jan 27, 2026 08:00AM Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 22, 2026 08:00AM Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 21, 2026 08:00AM Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 20, 2026 08:04AM Aspire Biopharma files patent for sublingual alprazolam formulation

Jan 20, 2026 08:00AM Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 14, 2026 08:00AM Aspire Biopharma implements 1-for-40 reverse stock split

Jan 14, 2026 08:00AM Aspire Biopharma Announces Reverse Stock Split

Jan 13, 2026 04:33PM Aspire Biopharma director Ajjarapu resigns from board

Jan 7, 2026 08:01AM Aspire Biopharma receives FDA guidance for sublingual aspirin drug

Jan 7, 2026 08:00AM Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Dec 18, 2025 08:30AM Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 12, 2025 05:00PM Aspire Biopharma gets Nasdaq extension to meet listing requirements

View Older Stories